Ken Griffin Sc Pharmaceuticals Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$4.86 - $6.39 $48,600 - $63,900	-10,000 Reduced 77.52%	2,900 $14,000
Q4 2023 Feb 14, 2024	BUY	$4.7 - $6.63 $47,000 - $66,300	10,000 Added 344.83%	12,900 $80,000
Q3 2023 Nov 14, 2023	SELL	$7.0 - $9.82 $147,000 - $206,220	-21,000 Reduced 87.87%	2,900 $20,000
Q2 2023 Aug 14, 2023	BUY	$8.94 - $11.74 $188,634 - $247,714	21,100 Added 753.57%	23,900 $243,000
Q1 2023 May 15, 2023	SELL	$5.59 - $9.47 $199,004 - $337,132	-35,600 Reduced 92.71%	2,800 $25,000

Q4 2022 Feb 14, 2023	BUY	$5.38 - $7.53 $138,804 - $194,274	25,800 Added 204.76%	38,400 $275,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $56,448 - $81,522	12,600 New	12,600 $82,000

26.7M

101K

13.9K

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $121M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.